SinoMab Announces that IND Application of SM17 for the Treat

SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP

SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP

jcnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jcnnewswire.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Hong Kong , China , Chinese , Willa Xue , Sinomab Bioscience Limited Stock Code , Significant New Drugs Development Of The Twelfth , Asia Corporate News Network , Sinomab Bioscience , National Medical Products Administration Of China , Drug Administration , Sinomab Announces , Domestic Clinical , Hong Kong Based , Mab Bioscience Limited , Stock Code , Investigational New Drug , National Medical Products Administration , Idiopathic Pulmonary Fibrosis , Sullivan Report , Executive Director , Chief Executive Officer , Significant New Drugs Development , Twelfth Five Year Plan Period , Thirteenth Five Year Plan , Chloe Chiu , Serena Zhang , Asia Corporate News ,